4.6 Review

Updates in the Evaluation and Management of Breast Cancer

期刊

MAYO CLINIC PROCEEDINGS
卷 93, 期 6, 页码 794-807

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2018.03.025

关键词

-

资金

  1. Janssen
  2. Bristol-Myers Squibb
  3. Takeda

向作者/读者索取更多资源

Breast cancer is the most commonly diagnosed cancer worldwide. More than 200,000 new cases of invasive breast cancer are diagnosed annually in the United States; approximately 40,000 patients die of the disease. The etiology of most breast cancer cases is unknown, although multiple factors predisposing to the disease have been identified. Apart from increasing age and female sex, these other factors account for only a minority of breast cancer diagnoses. This article provides an overview of the management of noninvasive and invasive breast cancer, which is often complex and varies according to patient factors, disease stage, and breast cancer subtype. Although much progress has been made, continued research endeavors are ongoing; enrollment of eligible patients in prospective clinical trials is an essential way to improve patient outcomes. (C) 2018 Mayo Foundation for Medical Education and Research

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据